NCT01960010

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

A Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 Ophthalmic Solution in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 403 (actual)
• Sponsor: Mimetogen Pharmaceuticals USA, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of MIM-D3 Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Conditions

• Dry Eye Syndromes

Interventions

Type	Name	Description
DRUG	MIM-D3 Ophthalmic Solution	1% MIM-D3 dosed BID
DRUG	Vehicle	Vehicle dosed BID

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2013-10-10
• Last updated: 2019-08-19

Locations

5 sites across 1 country: United States